Objective: To evaluate the factors a ecting overall survival (OS) and progression-free survival (PFS) in patients with limited stage-small cell lung cancer (LS-SCLC). Study Design: Descriptive study. Place and Duration of Study: Prof. Dr. Cemil Tascioglu City Hospital, Istanbul, Turkey from January 2002 to October 2019. Methodology: Data of 89 patients was analysed, who were treated with chemoradiotherapy (CRT) for LS-SCLC,of whom some had also received prophylactic cranial irradiation (PCI). The clinical course and survival rates of LS-SCLS patients treated with di erent treatment modalities, were evaluated and the prognostic factors were analysed by Cox-regression analysis. Results: The median age of the patients was 59.6 (39 83) years-old; 82% were men. The median follow-up duration was 20 (1 189) months. The median PFS and OS were 16 (95% CI, 13-18) months and 33 (95% CI, 25-41) months. Patients, who underwent PCI had better OS compared to patients who did not [54 (95% CI, 27-87) monthsvs. 19 (95% Cl,, 13-25) months, log-rank, p = 0.004]. Grade 3-4 hematologic toxicities were observed in 12 (13.5%) patients and grade 3-4 esophagitis was observed in 25 (28.1%) patients. Younger age, ECOG 0-1, stage I-II disease, complete response to CRT were good prognostic factors on OS and PFS. A complete response to CRT was also a good independent factor in terms of PFS and OS. Conclusion: In this study, younger age, better ECOG status, stage I-II disease, and complete response to CRT had a favourable impact on OS and PFS in LS-SCLC. In addition, PCI has been shown to increase survival in these patients.